HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price Target

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Nuvectis Pharma (NASDAQ: NVCT) and maintained a price target of $39. This indicates continued confidence in the company's performance and potential for growth.